UnitedHealthcare Rituximab (Rituxan & Biosimilars) prior authorization requirements (2026)
What UnitedHealthcare generally requires to approve Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123), for Commercial plans. Yes. UnitedHealthcare generally requires prior authorization for Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123).
Medical-necessity criteria UnitedHealthcare generally applies
Prior authorization required. Riabni, Ruxience, and Truxima are the preferred rituximab products; non-preferred Rituxan requires documented intolerance/contraindication/serious adverse event to all three preferred products plus physician attestation. RHEUMATOID ARTHRITIS initial: moderate-to-severe disease activity AND concurrent methotrexate (or documented MTX contraindication/intolerance) AND failure/contraindication/intolerance to at least one TNF inhibitor (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab); not used in combination with another targeted immunomodulator. Dosing per FDA labeling (one course = two 1000 mg IV infusions 2 weeks apart). Initial authorization up to 12 months; continuation up to 12 months with a documented positive clinical response.
Diagnoses that commonly support medical necessity
ICD-10-CM diagnoses frequently associated with medical necessity for Rituximab (Rituxan & Biosimilars). Confirm the covered diagnosis list against the current UnitedHealthcare policy.
Commonly required documentation
- Diagnosis and disease-activity documentation
- concurrent MTX or MTX intolerance
- documented prior TNF-inhibitor failure
- preferred-product trial/intolerance documentation.
Situations to verify before submitting
UnitedHealthcare may not cover Rituximab (Rituxan & Biosimilars) in these situations. Verify against the current policy rather than assuming a denial:
- Not covered in combination with another targeted immunomodulator/biologic or a JAK inhibitor for RA
- Rituxan Hycela (rituximab/hyaluronidase) is unproven / not medically necessary for non-oncology indications
How to submit
- Method: UnitedHealthcare provider portal (medical benefit drug review)
- Portal: UnitedHealthcare Provider Portal
Sources & verification
Source: UHC Commercial Medical Benefit Drug Policy 2026D0003AO Rituximab (eff 2026-01-01). Codes J9312, Q5115, Q5119, Q5123. Note: UHC RA criteria require a prior TNF-inhibitor trial and do NOT name a rheumatologist prescriber requirement. Last verified 2026-06-17.
Frequently asked questions
Does UnitedHealthcare require prior authorization for Rituximab (Rituxan & Biosimilars)?
Yes. UnitedHealthcare generally requires prior authorization for Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123).
What does UnitedHealthcare require to approve Rituximab (Rituxan & Biosimilars)?
Prior authorization required. Riabni, Ruxience, and Truxima are the preferred rituximab products; non-preferred Rituxan requires documented intolerance/contraindication/serious adverse event to all three preferred products plus physician attestation. RHEUMATOID ARTHRITIS initial: moderate-to-severe disease activity AND concurrent methotrexate (or documented MTX contraindication/intolerance) AND fa… Always confirm against the current UnitedHealthcare policy.
How long does a UnitedHealthcare prior authorization take?
Turnaround varies by plan and submission method. Check the UnitedHealthcare portal for current timeframes.
Submitting Rituximab (Rituxan & Biosimilars) to UnitedHealthcare?
Praxigen checks your clinical note against these criteria before you submit and drafts a policy-cited appeal if it is denied. You review and submit; nothing is sent automatically.